Results 31 to 40 of about 807 (164)

Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study [PDF]

BMC Cancer
Background Cancer patients are at an elevated risk for SARS-CoV-2 infection and require vigilant monitoring. The efficacy and safety of Azvudine in treating COVID-19 among this vulnerable group remain under-researched. Methods We conducted a multicenter,
Lei Li, Wenjie Liu, Ling Wang, Mengzhao Yang, Juan Wang, Guotao Li, Guowu Qian, Shixi Zhang, Donghai Liu, Hong Luo, Silin Li, Donghua Zhang, Zujiang Yu, Zhigang Ren   +13 more
doaj   +2 more sources

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study [PDF]

BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao, Daming Wang, Mengzhao Yang, Chunyu Zhao, Ming Cheng, Silin Li, Donghua Zhang, Hong Luo, Guowu Qian, Ling Wang, Shixi Zhang, Guotao Li, Guangming Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +2 more sources

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundAzvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19.
Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng   +29 more
doaj   +3 more sources

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

View
Kidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective
Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan   +13 more
doaj   +2 more sources

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj   +3 more sources

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes [PDF]

iScience
Summary: Azvudine and nirmatrelvir-ritonavir are prioritized treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in hospitalized patients with COVID-19 and pre-existing diabetes remains unknown.
Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren   +18 more
doaj   +2 more sources

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

View
Although azvudine has become a priority in the treatment of SARS‐CoV‐2, its effectiveness and safety among COVID‐19 patients who already have chronic respiratory diseases (CRDs) have not been sufficiently validated.
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
doaj   +2 more sources

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

BMC Infectious Diseases
Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between ...
Peng Su, Cong-xian Yang, Xing-guang Wang
doaj   +3 more sources

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +3 more sources

Validation study for assessing COVID-19 pneumonia treatments [PDF]

Scientific Reports
This study investigates the effectiveness of Azvudine and nirmatrelvir-ritonavir (Paxlovid) in treating COVID-19 pneumonia through an analysis of real-world clinical data.
Kaibin Lin, Bing Zhou, Yi Wu, Zheng Wang, Shu Li, Yuanyuan Li, Fen Li, Yang Xue, Zirou Liu, Jiafen Liao   +9 more
doaj   +2 more sources